Mytos

Company Information

Mytos develops automated cell culture systems aimed at transforming human cell manufacturing. Their technology streamlines traditionally manual processes, making cell culture more scalable, consistent, and efficient. This innovation addresses the increasing demand in sectors like drug discovery and cell therapy.

Grants/Incubators/Funders:

We use the Business Model Canvas (BMC), which captures what the startups offers, how it reaches its customers and how profitable it could be.
Key Partnerships

What strategic collaborations do they have, and how do these enhance the company’s capabilities or reduce risk, etc.

  • Companies: Exact companies unknown, but product already deployed
  • Investors: Buckley Ventures, IQ Capital, and Wing VC ($19M overall)
  • Academic Institutions: Unknown
Key Activities

How are they creating value, improving relationships with customers, increasing operational efficiency, etc.

  • Value: Increases efficiency of automated cell manufacturing and expands to new cells types
  • Method: Automates differentiation of two cell types invaluable for disease modelling
  • Relationships: Unknown
Key Resources

What resources/assets do they need to deliver value.

  • Resources: energy, complex hardware and software
  • Assets: proprietary tech
  • Team: Specialists - engineering & biotechnology
Value Proposition

What are they offering, how are they meeting customers needs, how are they differentiable from competition, etc.

  • Offer: huge efficiency gain, less human intervention required
  • Quality: Ensures quality, removes human error
  • Differentiation: highly scalable
Customer relationships

How will they build loyalty, maintain good relationships, what kind of relationships do we expect, etc.

  • Needs: Easy integration with existing infrastructure
  • Support: Provide ongoing technical support
Channels

How will they reach their customers, how is their cost efficiency, customer acquisition, and retention, how will they distribute, etc.

  • Sales: direct sales, pharma & biotech companies
Customer Segments

Who are they serving, what is the target market, market size, etc.

  • Targets: B2B

Cost Structure

What are the major fixed and variable costs.

  • Variable: materials for production, distribution, and customer support services
  • Fixed: Salaries, R&D expenses, and facility operations
Revenue Streams

how will they make money, what is the pricing structure, any additional/creative revenue streams, etc.

  • Physical sales: Proceeds from systems
  • Recurring: Maintenance/support agreements
  • Licensing: potential income from licensing agreements
We use Porter’s five forces to evaluate the company’s competitive position and dynamics of the market and any external pressures

1. Threat of New Entrants

➕

  • Huge barrier to entry (expertise and large initial funding required).

➖

  • Some automation technology is open-access/freely available.

2. Threat of Substitutes

➕

  • Efficient automation is difficult to substitute.

➖

  • Advanced robotics or more efficient automation is always possible.

3. Bargaining Power of Suppliers

➕

  • If expertise is internal, minimal dependence on anything except hardware.

➖

  • If hardware components become more niche, might become problematic.

4. Bargaining Power of Buyers

➕

  • The large efficiency gain, and lack of immediate competitors places it well.

➖

  • Large biotech and pharma companies always hold large pricing power.

5. Intensity of Current Competition

➕

  • No current competition with these two cell types (neural progenitors & cardiomyocytes)

➖

  • Larger pharma companies could use their scale to catch up quickly and would be able to price their products more competitively.

Resources